Metabolix (YTEN)
(Delayed Data from NSDQ)
$0.24 USD
0.00 (1.92%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.24 0.00 (0.42%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
YTEN 0.24 0.00(1.92%)
Will YTEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for YTEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for YTEN
Corteva, Inc. (CTVA) Beats Q1 Earnings and Revenue Estimates
ADT and CarMax have been highlighted as Zacks Bull and Bear of the Day
YTEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Under-$3 Consumer Staple Stocks Wall Street Analysts Recommend Buying
Metabolix, Inc. (YTEN) Reports Q3 Loss, Misses Revenue Estimates
Corteva, Inc. (CTVA) Reports Q3 Loss, Tops Revenue Estimates
Other News for YTEN
Yield10 Bioscience files to sell 6.38M shares of common stock for holders
Yield10 Bioscience files to sell 6.38M shares of common stock for holders
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Hold Recommendation on Yield10 Bioscience Amid Commercialization and Capital Uncertainties